Introduction
Autoimmune thyroiditis is not generally recognised as a risk factor for coronary artery disease. Yet in 1967 Bastenie et al found in a histopathological investigation that a fifth of men and nearly a half of women with fatal myocardial infarction had lymphocytic thyroiditis at necropsy whereas thyroiditis in men and women who died of other causes was present in only 10% of cases.' In the same year others pointed out the association of coronary artery disease to minimal impairment of thyroid function.2 When thyroid stimulating hormone measurement became a routine clinical procedure and the thyrotrophin releasing hormone test was introduced, it was possible to measure minimal impairment of thyroid function.
Tieche et al found in a cross sectional study that women with a thyroid stimulating hormone value in the upper part of the normal range had double the incidence of ischaemic heart disease of women with thyroid stimulating hormone values in the lower part of the normal range. 3 A prospective study on Finnish subjects showed that the presence of thyroid antibodies doubled the incidence of coronary artery disease over a five year period. 4 The association of coronary artery disease with autoimmune thyroiditis has been noted especially in women, but cardiologists still do not list minimal impairment of thyroid function as an important risk factor in coronary artery disease. We therefore compared the thyroid function in women aged 60 years or under with coronary artery disease proved by angiography with that in women with normal coronary angiograms. 
Patients and methods

Results
The mean age in the control group was 52 years (SD 8 9) and in patients with coronary artery disease 51 years (5 8 In regard to your expert's two criticisms in his first paragraph, we chose 12 patients with severe coronary artery disease to compare with the controls. TRH tests were done, as stated, on 12 consecutive patients with severe coronary artery disease. His criticism of the numbers studied is surely met by these statistics.
We would also like to mollify your expert by changing the title of the paper to "Exaggerated response of thyroid stimulating hormone to thyrotrophin releasing hormone-a risk factor in women with coronary artery disease." We would add a few key references in case other readers beside your expert are unaware of the importance of this test in borderline hypothyroidism.
Reply from the editor 6 I actually found this rather an interesting study; the pity of it is that the science is rather woolly and the authors' claim is therefore not validated. However, I am sure it should be pursued and, with improved data, published.
More detailed criticisms are as follows.
(1) A larger patient and control sample is required.
(2) More attention should be given to the methodology, particularly the TSH assay and the antibody tests. Since so much depends on the TRH test full details of the TSH assay should be given, and in particular it is essential that all samples from both groups should be measured in the same assay. What is the coefficient of variation of the assay? I am a little surprised at the method of thyroid antibody detection and think this should be looked at properly using one of the well validated quantitative tests; also they should do both thyroglobulin and microsomal antibody titres.
(3) Expression of results: a small point but, rather than giving tables of all the individual TRH tests, it would be more useful to see the means for each group plotted in a diagram. They do not quote the mean free thyroxine index for each group and clearly that should be given. A table to show the means (or medians) of all the measurements for each group might be helpful.
(4) Interpretation of results: one can dismiss apparent differences in antibody frequency because of the small numbers and the poor methodology. That leaves only the response of TRH to be explained. I have a suspicion that this may relate to cigarette smoking rather than indicate borderline hyothyroidism. The obvious way to look at this would be to do TRH tests in a group of cigarette smokers who do not have coronary artery disease, and, incidentally, some note should be made of the numbers of cigarettes smoked by the individuals in the study. It might also be interesting to assay all the samples for prolactin as it may be possible to show significant differences between groups in prolactin response to TRH also.
In conclusion I agree that the paper is too weak scientifically to be published as it stands, but I do think the authors should be encouraged to pursue this work and resubmit it. 
Statistics
We went back to our statistician. He emphasises the significance of the difference in the TRH tests in our two groups and points out that greater numbers will give precision regarding the risk factor without changing the significance.
TSH assays
As requested, we have given further details regarding the TSH assay, in particular, the interassay coefficient of variation. We do appreciate that our samples from both groups would have been best done in the same assay. This defect is mitigated by the coefficient of variation, which has been given. It did seem to us that any alteration in the assays would balance out in the two groups but do appreciate that this is a very valid and fair criticism.
We do hope that when the above changes have been included in the paper that you and your expert will find it acceptable.
PS It is as difficult to guess the identity of your second expert as it was easy to guess the first. I have had a weekend to reflect on your expert's suggestion, "Dare I say that it might be more appropriate for the correspondence columns of the Lancet." It might be more sensible to submit the letter to the BMJ correspondence columns since your journal was our first choice with this article. We now have 12 controls, whereas in the article submitted to you there were only 11 controls for the 12 patients. Your referee failed to realise the great problem of getting controls since it is unethical to submit patients for coronary angiography unless there is good reason for suspecting coronary artery disease. When our paper is published it will be only the second that has ever compared thyroid function in two groups where the presence or absence of coronary artery disease has been confirmed by coronary angiography. There are 10 out of our 12 patients with coronary artery disease who had an abnormal TRH test and only two in the controls, of whom one had previously had a thyroidectomy. For the statistically illiterate this means that the findings could have occurred by chance once in 125 times. If the subject who had had a thyroidectomy is excluded the chance is one in 250 times. We would offer to send the data to anyone interested, hoping that they would do similar studies to confirm or refute our findings. Confirmation would be a major breakthrough in the aetiology and prevention of coronary artery disease in women. None ofthe patients in our study attended my clinics since this would have produced a bias because of my known interest in the association of coronary artery disease to the thyroid, dating back to my first paper on the subject in the Lancet in 1967. If this information is to be published as a letter it would be tempting to point out why it has not been accepted as an article. The identity of the first referee was obvious since there is only one "expert" who could state "I am not aware of any benefit having been demonstrated of measuring a TSH response to TRH in primary hypothyroidism or in incipient thyroid dysfunction." It could be pointed out that you kindly referred the article to a second referee, who suggested alterations with which we complied. He rejected the revised article on the grounds that, inter alia, "patients who smoke heavily often also consume excess alcohol, and there is no doubt that TRH tests may be abnormal in patients with alcoholic liver disease" (incidentally, this statement is incorrect).
At this stage the revised manuscript was sent to the BMJ's statistical adviser.
Report of the statistical referee on the revised manuscript 30 November 1984 This is a small study, with insufficient explanation given of the source and nature of the "control" group. These should be presented together with their justification-why, for example, was age matching not considered when such factors as serum cholesterol and blood pressure were to be considered? Why was the coronary artery disease group restricted to be aged 60 years or under but apparently not the "control" group (see means and standard deviations in results section)?
The unmodified x2 test, if this implies without the continuity correction, is unsatisfactory for these data on such small numbers. It Regarding Dr Fowler's publication on "Exaggerated responsive ness to thyrotrophin releasing hormone-a risk factor in women with coronary artery disease," I find it interesting that Dr Fowler has been so persistent with his request that this should be published. It seemed to me from memory that there were two problems with the study. One was that it was performed inadequately and the other was that the hypothesis seemed unlikely. Whereas I can understand that on the latter grounds you might be accused of undue bias and unwillingness to take a risk, it did seem to me that the study was inadequately performed and the criticisms that I raised regarding the performance of the study still remain unaltered unless, of course, in the continuing correspondence with you some of these have been met by extending the numbers used or by removing some of the other biases that seemed to be associated with the selection of patients. The most practical step to be taken in preventing a young child from experiencing what was a mild but definitely anaphylactic reaction to eating fish is obviously to exclude fish and fish products from the diet. It would be wise to exclude both fully cooked and shell fish. It is not possible to predict how long an allergic child will remain sensitive, but I suspect that with fish, unlike allergy to milk which usually resolves in the second year, this may be a long standing problem. The coexistence of mild asthma confirms that the child is atopic-that is, likely to be easily sensitised to ordinary environmental anotypes. Dietary control may be difficult during the early toddler years when the child is not necessarily open to persuasion. It will therefore be necessary to have powerful antihistamines on hand, such as chlorphenira- The syndrome is a rare variant of parkinsonism, resistant to all conventional treatment with unrelenting progression of death, usually within eight years of the onset. The deeper grey matter of basal ganglia, tectal region, brainstem, and cerebellum is enveloped in neurofibrillary tangles (without senile plaques) with nerve cell loss, gliosis, and granulovacuolar degeneration. Men are particularly affected (ratio 5:2). The onset is typically in the early SOs with unsteady gait, abrupt falls (often backwards), altered vision, slurred speech, and dysphagia. In the early stages it is not unusual for one symptom to predominate. Characteristically there is a fixed, wide eyed stare, mask like facies, and fixed forward flexion of the neck with increased tone. The head moves rather than the eyes. There is a spastic dysarthria, pseudobulbar palsy, extreme rigidity, and bilateral extensor plantar responses. The end stage is of total rigidity, anarthria, aphagia, and inanition. All patients develop voluntary paralysis of downward gaze with a progressive paralysis of voluntary and later pursuit eye movements (synonym: progressive supranuclear palsy) until the eyes are fixed centrally, even in sleep, with bilateral ptosis. It is the severity of the ophthalmoplegia, rather than its presence, which separates the syndrome from Parkinson's disease, vascular disease, or senility. Mental activity is appreciably slow in timing and activation but, although the term "subcortical dementia" is used, verbal and perceptuomotor capacities are often strikingly preserved. There is no response to dopaminergic drugs. Temporary improvements with shunt procedures and methysergide have been claimed. The aetiology is unknown.
There is no evidence for a toxin or slow virus. There are no familial cases unless one considers the syndrome of Mata et al.'-E M R CRITCHLEY, consultant neurologist, Preston.
